HC comparative bioavailability standards
Comparative Bioavailability Standards: Formulations Used for Systemic Effects
Current edition
Adopted 2012/12/08, revised 2018/06/08, effective 2018/09/01
Current edition
Adopted 2012/12/08, revised 2018/06/08, effective 2018/09/01
About this standard
Sets the pharmacokinetic acceptance standards for bioequivalence and comparative bioavailability, with special standards for modified-release, critical dose and highly variable drugs. Standards for immediate-release products were replaced by ICH M13A from December 27, 2025.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
Canada
- Bioequivalence acceptance limits, critical dose and highly variable drugsBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.